Maria Hilado

Actavis, Inc. is a pharmaceutical company. It focuses on the development and distribution of generic products. The company engages in developing, manufacturing and marketing generic, branded generic, legacy brands and over-the-counter products. It operates its business in three segments: Actavis Pharma, Actavis Specialty Brands and Distribution. The Actavis Pharma segment develops and out-licenses generic pharmaceutical products outside the U.S. through its medis third-party business. The Actavis Specialty Brands segment engages in developing and marketing biosimilars products in women's health, oncology and other therapeutic categories. The Distribution segment distributes generic, select brand pharmaceutical products, vaccines, injectables and over-the-counter medicines from suppliers to independent pharmacies, alternate care providers, pharmacy chains and physicians offices. The company was founded by Allen Y. Chao and David C. Hsia in 1984 and is headquartered in Parsippany, NJ.

Pharmaceutical Product Development LLC engages in the operation of a global contract research organization, which provides drug development, laboratory and lifecycle management services. It offers adaptive trial design, bio analytical lab, bio similar development, biostatistics, GMP lab, clinical supplies, trial monitoring, CMC regulatory, data management, dental pain clinic, real-world outcomes, site intelligence and activation, central lab, global regulatory affairs, IRT systems, late stage research, medical communications, device and diagnostics, medical writing, nonclinical development and regulatory consulting and intelligence, regulatory development, innovation and vaccine sciences. The company was founded by Fredric N. Eshelman in 1985 and is headquartered in Wilmington, NC.

Curia Global, Inc. engages in drug research and development, and manufacturing. It offers drug delivery, drug development, analytical services, API development and manufacturing, and drug product solutions. The company was founded by Thomas E. D'Ambra on June 19, 1991 and is headquartered in Albany, NY.

Kythera Biopharmaceuticals LLC operates as a clinical-stage biopharmaceutical company. It focuses on the discovery, development, and commercialization of novel prescription products for the aesthetic medicine market. The company was founded by Jay Edward Birnbaum, Amit D. Munshi, Nathaniel Eames David, and Keith R. Leonard, Jr. on June 3, 2004 and is headquartered in Westlake, CA.

Ally Commercial Finance LLC provides financial services to middle market businesses in the aircraft, apparel, automotive, transportation, electronics and grocery industries. The company's products include financing for business acquisitions, project financing, asset-based lending, accounts receivable management, equipment finance and leasing, bankruptcy and transitional financing to help firms through downturns in business. Ally Commercial Finance was founded in 1999 and is headquartered in Southfield, MI.

Galderma SA develops and markets therapeutic and aesthetic solutions for dermatology. It provides medical dermatological solutions for acne, rosacea, psoriasis and other steroid-responsive dermatoses, onychomycosis, pigmentary disorders, skin cancer and medical aesthetic and corrective solutions for skin senescence. The company was founded in 1981 and is headquartered in Paris, France.

YMCA of Greater New York operates as a community service organization. The company was founded in 1852 and is headquartered in New York, NY.

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1982 and is headquartered in Dublin, Ireland.

Allergan GI Corp. develops peptide therapeutics for the treatment of gastrointestinal disorders. It provides RM-493 a small-peptide melanocortin-4 receptor agonist, for the treatment of obesity and diabetes, and RM-131 a small-peptide ghrelin agonist, for the treatment of diabetic gastro paresis and other gastrointestinal functional disorders. The company was founded by Bart Henderson and Elizabeth Stoner in 2008 and is headquartered in Madison, NJ.

PPD, Inc. engages in the provision of drug development services to the biopharmaceutical industry, focuses on helping customers bring their new medicines to patients around the world. It operates through the Clinical Development Services and Laboratory Services segments. The Clinical Development Services segment focuses in early development/Phase I, patient recruitment and enrollment, investigator site management, Phase II-IV clinical trial management, medical communications and various peri- and post-approval services. The Laboratory Services segment comprises of bioanalytical, vaccine sciences, GMP, central lab and biomarker testing. The company was founded by Fred Eshelma in 1985 and is headquartered in Wilmington, NC.

Allergan Plc is a global pharmaceutical company that develops, manufactures, and markets branded pharmaceutical, device, biologic, surgical, and regenerative medicine products for patients worldwide. The private company is based in Madison, NJ, with operations in approximately 100 countries. The company has a broad portfolio of leading brands and products in various therapeutic categories, including central nervous system, eye care, medical aesthetics, dermatology, gastroenterology, women's health, urology, and anti-infective. Allergan is an industry leader in open science, a model of research and development that focuses on identifying and developing innovative ideas and innovation for better patient care.